ALK and cancer: It is not unlikely that it will be necessary to combine ALK inhibitors with other inhibitors/drugs that either target downstream pathways—targeting the PI3K-Akt-mTOR pathway appears to be an especially promising strategy—or that otherwise influence ALK degradation, ALK phosphorylation, and cancer cell proliferation and apoptosis in general.